ع
Rene Haas who heads the Cambridge-based designer of processors found in more than 350 billion devices worldwide described health as the killer application for artificial intelligence during an interview released that day. The executive who left the board of AstraZeneca in April argued that the technology will compress both the timeline for inventing new drugs and the duration of testing many of which currently require 20 years with a 95 per cent failure rate according to his assessment. A separate analysis published by the American Association for Cancer Research in 2026 noted that 20 new anticancer therapies and several AI-based early detection tools gained regulatory approval in the preceding 12 months underscoring the sector’s accelerating pace.
Haas told the BBC that modelling a cell a human or the interaction between DNA markers and cancer remains too complex for humans and current AI systems. “I believe in our lifetime AI will help cure cancer” he said adding that successive improvements in models and computing power will enable solutions. Data from ClinicalTrials.gov retrieved in August 2026 showed more than 4,000 registered studies worldwide referencing artificial intelligence or machine learning with oncology representing the largest single category at nearly 13 per cent of such trials.
The Arm chief executive highlighted an acute supply constraint across the semiconductor industry that he expects to persist for some time. Demand for the company’s Neoverse artificial intelligence products doubled from roughly 1 billion dollars to more than 2 billion dollars in just five months with major customers including Meta Oracle Cloudflare and SK Telecom according to figures he provided. A UK government adoption plan for life sciences published earlier in 2026 identified a similar compute bottleneck noting that demand for specialist AI supercomputing resources continues to outstrip available supply even after upgrades to systems such as the DAWN supercomputer.
Optimistic forecasts have also come from other technology leaders. Google’s president and chief investment officer Ruth Porat stated in late 2025 that artificial intelligence should be able to cure cancer within our lifetime citing tools such as DeepMind’s AlphaFold as evidence of its potential to transform drug discovery. Anthropic chief Dario Amodei and Google DeepMind co-founder Demis Hassabis have likewise suggested that cures for most diseases including many cancers could arrive within five to 15 years although such timelines remain contested.
Computational oncology professor Florian Markowetz at the University of Cambridge offered a more measured perspective in a July 2026 interview. He told IFLScience that while AI will improve early detection diagnosis and treatment a universal cure for cancer is improbable because the disease encompasses many distinct mechanisms across different organs and tissues. The professor emphasised that progress will instead deliver better drugs longer healthier lives and earlier spotting of tumours rather than complete eradication.
Ongoing UK initiatives illustrate practical application of these technologies. A project at the University of Oxford backed by the national sovereign AI supercomputer DAWN has already produced high-quality predictions for personalised cancer vaccines with plans to manufacture a prototype in Britain within the next year according to an update issued in June 2026. The American Association for Cancer Research progress report recorded 18.6 million cancer survivors in the United States in 2025 equivalent to 5.5 per cent of the population following a 34 per cent decline in the overall death rate since 1991.
